Interview with: Thomas S. Jensen, Intomics, a sponsor company at the marcus evans Discovery Summit 2014, on taking better advantage of drug discovery data available in the public domain

  • 116 views
Uploaded on

Interview with: Thomas S. Jensen, Intomics, a sponsor company at the marcus evans Discovery Summit 2014, on taking better advantage of drug discovery data available in the public domain

Interview with: Thomas S. Jensen, Intomics, a sponsor company at the marcus evans Discovery Summit 2014, on taking better advantage of drug discovery data available in the public domain

More in: Business
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Be the first to comment
    Be the first to like this
No Downloads

Views

Total Views
116
On Slideshare
0
From Embeds
0
Number of Embeds
1

Actions

Shares
Downloads
0
Comments
0
Likes
0

Embeds 0

No embeds

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
    No notes for slide

Transcript

  • 1. Doubling Drug Discovery Success Interview with: Thomas S. Jensen, Chief Executive Officer, Intomics “Pharmaceutical companies are not always taking full advantage of publicly available data,” according to Thomas S. Jensen, Chief Executive Officer, Intomics. “Instead of focusing on a few experiments and basing their decisions on them, they can use quality data available publicly in an integrative approach and improve, sometimes even double, the success rate of their follow- up experiments,” he recommends. Intomics is a sponsor company at the marcus evans Discovery Summit 2014, in Lisbon, Portugal, 31 March - 1 April. What are the biggest issues in drug discovery today? There has been a paradigm shift in the area of data-driven drug target identification, with biotechnology measurement capabilities continuously increasing and data generation getting cheaper, leading to more and more data. The challenge here is in getting a holistic view of the underlying biology from that data and using it to find the right targets for the right patients in the right disease population. How could pharma companies better leverage the research conducted within the organisation? Our experience with clients is that they start out with a very simplistic approach but quickly realise that much of the information they need in order to leverage their activities already exists. They may have generated it in-house in a different project or context, or it is in the public domain. The more high quality data they base decisions on, the more accurate they will be and the better outcomes they will get. It will take less time to go through a given phase. When picking the right patients for a given drug, they will have a much higher response rate in the clinical trials. Utilising data available in the public domain leads to more cost effective drug discovery. How does Intomics’ database support drug discovery? We have taken the research data available publicly, and spent time cleaning and reanalysing it to create whole new ways of looking at it, to help in extracting their true biological significance. Most individuals typically have 400,000 - 800,000 mutations in their genes. Across a cohort of patients, that translates into millions of mutations. The question is, which of those lead to the disease or can help identify the patients most likely to respond to a given treatment? Our method is network-based inter- pretation of genetic data, where we can pinpoint the biological sub-systems being mutated. We have a database of how biological molecules interact, how the proteins touch each other inside the cell, which provides a strong indication of functional relationships. It is quite similar to how social networks such as Facebook or Linkedin work, and helps companies analyse and interpret the various types of big data sets they are generating or have access to. Any final comments? Companies are not taking full advantage of the possibilities that are available to them in this era of big data. The better they understand a disease, the better options they have for taking the right targets to the right patients, and the higher the success probability of their project will be, irrespective of where most of the data was generated. Utilising data available in the public domain leads to more cost effective drug discovery
  • 2. The Pharma Network – marcus evans Summits group delivers peer-to-peer information on strategic matters, professional t r e n d s a n d b r e a k t h r o u g h innovations. Please note that the Summit is a closed business event and the number of participants strictly limited. About the Discovery Summit 2014 This unique forum will take place at the Grande Real Villa Itália Hotel & Spa, Cascais, Lisbon, Europe, 31 March - 1 April 2014. Offering much more than any conference, exhibition or trade show, this exclusive meeting will bring together esteemed industry thought leaders and solution providers to a highly focused and interactive networking event. The Summit includes presentations on boosting pipeline productivity, understanding disease mechanism, finding promising targets, and reviewing economic and regulatory challenges. www.discovery-summit.com Contact Sarin Kouyoumdjian-Gurunlian, Press Manager, marcus evans, Summits Division Tel: + 357 22 849 313 Email: press@marcusevanscy.com For more information please send an email to info@marcusevanscy.com All rights reserved. The above content may be republished or reproduced. Kindly inform us by sending an email to press@marcusevanscy.com About Intomics Intomics, located in Copenhagen, Denmark, is a consultancy and contract research organization highly specialized in analysis and integration of biomedical big data, both at molecular level and patient level. Through the use of our world-leading expertise, unique data sets, and our proprietary systems biology platform, we help our clients in the pharmaceutical industry identify the right drug targets for the right patients. www.intomics.com About marcus evans Summits marcus evans Summits are high level business forums for the world’s leading decision-makers to meet, learn and discuss strategies and solutions. Held at exclusive locations around the world, these events provide attendees with a unique opportunity to individually tailor their schedules of keynote presentations, case studies, roundtables and one-to-one business meetings. For more information, please visit: www.marcusevans.com Upcoming Events Evolution Summit (North America) - www.evolutionsummit.com Evolution Summit (Europe) - www.evolution-summit.com To view the web version of this interview, please click here: www.discovery-summit.com/ThomasSJensen